Enflicoxib for canine osteoarthritis: A randomized, blind, multicentre, non-inferiority clinical trial compared to mavacoxib.

Marta SalichsLlorenç BadiellaPatxi SarasolaJosep M Homedes

Published in: PloS one (2022)

Enflicoxib is efficacious and safe for the treatment of pain and inflammation in any stage of canine osteoarthritis with a faster onset of action compared to mavacoxib.

Keyphrases

clinical trial
rheumatoid arthritis
knee osteoarthritis
study protocol
chronic pain
double blind
pain management
open label
phase ii
randomized controlled trial
cross sectional
combination therapy
replacement therapy